Laser Photonics Secures $1.05 Million Deal to Automate Pharmaceutical Manufacturing
Orlando, Monday, 24 August 2026.
Laser Photonics secured a $1.05 million contract on August 24, 2026, delivering high-speed systems capable of laser-drilling up to 70,000 pharmaceutical tablets per hour for precise controlled-release medication.
Pharmaceutical Contract Specifications
Laser Photonics Corporation (NASDAQ: LASE) announced on 24 August 2026 that it has secured a $1.05 million purchase order from a major U.S. pharmaceutical manufacturer [1]. The contract covers the delivery of the TD-70 high-speed pharmaceutical tablet drilling system, which is designed to streamline laser-based manufacturing processes within high-precision supply chains [1]. This specialized system features a throughput capacity of up to 70,000 tablets per hour and includes a dual-camera vision system for real-time inspection and rejection [1]. The order encompasses not only the drilling machinery but also tablet handling tooling, conveyor transport, and full IQ/OQ/PQ validation packages required for production-scale deployment [1].
Strategic Expansion into Healthcare Markets
This commercial contract highlights an expanding adoption of industrial laser technology beyond traditional defense and automotive applications [1]. The agreement follows the company’s announcement in May 2026 regarding an expansion into precision medical device manufacturing to increase commercial traction in regulated healthcare markets [1]. Ann Tewari, Interim President of Laser Photonics, stated that the order reflects the strength of the company’s subsidiary, CMS Laser, in winning customers based on engineering capability and process quality [1]. The systems will be manufactured at the CMS Laser facility in Winter Park, Florida, utilizing high-speed precision laser drilling to create orifices for controlled-release tablets with minimal variability [1].
Market Performance and Stock Context
This announcement comes amidst a period of significant volatility for Laser Photonics stock, which previously surged over 150% intraday on 2 June 2026 following news of a defense evaluation process [2]. While that earlier movement was driven by the selection of its Laser Shield Anti-Drone system for a U.S. Department of War technical review, the current order represents a secured commercial contract rather than an evaluation [2]. As of 23 August 2026, Laser Photonics stock traded at $2.32 per share, reflecting a year-to-date decline of approximately 18.5% prior to this latest development [2]. Message volumes regarding LASE on trading platforms had surged over 8,300% during the seven-day period ending 23 August 2026, indicating high investor attention leading into this announcement [2].